Shuttle Pharmaceuticals Holdings, Inc. last reported quarterly results on Feb 17, 2026, for Q4 FY2025 (the quarter ended Dec 31, 2025): diluted EPS of -$0.95. It usually reports 44–57 days after a quarter ends.
Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 44–57 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.
| Released | Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|---|
|
Feb 17, 2026
48 days after quarter end
|
Q4 FY2025
ended Dec 31, 2025
|
—
|
-3
-63.6%
|
-0.95
+88.2%
|
|
Feb 26, 2025
57 days after quarter end
|
Q4 FY2024
ended Dec 31, 2024
|
—
|
-2
+2.6%
|
-8.04
|
|
Nov 13, 2024
44 days after quarter end
|
Q3 FY2024
ended Sep 30, 2024
|
—
|
-4
-111.1%
|
-39.83
-4276.9%
|
|
May 14, 2024
44 days after quarter end
|
—
ended Mar 31, 2024
|
—
|
—
|
—
|
|
Nov 14, 2023
45 days after quarter end
|
—
ended Sep 30, 2023
|
—
|
—
|
—
|
|
Aug 15, 2023
46 days after quarter end
|
—
ended Jun 30, 2023
|
—
|
—
|
—
|
|
May 26, 2023
56 days after quarter end
|
—
ended Mar 31, 2023
|
—
|
—
|
—
|
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- SHPH (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Gaithersburg, MD
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1757499
- Former names
- Shuttle Pharmaceuticals Holdings, Inc. (until Oct 22, 2026)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.